Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Fig. 2

Best percentage change from baseline in target lesions by treatment group and indication (FAS). Footnote: ESCC esophageal squamous cell carcinoma, PD progressive disease, Q2W once every two weeks, QW once weekly, SCCHN squamous cell carcinoma of the head and neck, SD stable disease, UNK unknown

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us